Immune regulation of multiple sclerosis

Handbook of Clinical Neurology

Volumn 122, Issue , 2014, Pages 3-14

  Hartung, Hans Peter ^a   Aktas, Orhan ^a   Menge, Til ^a   Kieseier, Bernd C ^a  

^a Department of Orthopedic Surgery   (Germany)

Author keywords

Adaptive immunity; B cells; Blood brain barrier; Chemokines; Cytokines; Innate immunity; Macrophages; Matrix metalloproteinases; T cells

Indexed keywords

CHEMOKINE; CYTOKINE; IMMUNOLOGIC FACTOR; MATRIX METALLOPROTEINASE;

ADAPTIVE IMMUNITY; ANIMAL; ARTICLE; B LYMPHOCYTE; B-CELLS; BLOOD BRAIN BARRIER; CYTOLOGY; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; MACROPHAGE; METABOLISM; MULTIPLE SCLEROSIS; PATHOLOGY; T LYMPHOCYTE; T-CELLS;

ADAPTIVE IMMUNITY; B-CELLS; BLOOD-BRAIN BARRIER; CHEMOKINES; CYTOKINES; INNATE IMMUNITY; MACROPHAGES; MATRIX METALLOPROTEINASES; T-CELLS;

ADAPTIVE IMMUNITY; ANIMALS; B-LYMPHOCYTES; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

EID: 84893439966     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52001-2.00001-7     Document Type: Chapter

References (110)

1. Agrawal S.M., Lau L., Yong V.W. MMPs in the central nervous system: where the good guys go bad. Semin Cell Dev Biol 2008, 19:42-51.
2. Aktas O., Smorodchenko A., Brocke S., et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 2005, 46:421-432.
3. Aktas O., Prozorovski T., Zipp F. Death ligands and autoimmune demyelination. Neuroscientist 2006, 12:305-316.
4. Aktas O., Schulze-Topphoff U., Zipp F. The role of TRAIL/TRAIL receptors in central nervous system pathology. Front Biosci 2007, 12:2912-2921.
5. Aktas O., Ullrich O., Infante-Duarte C., et al. Neuronal damage in brain inflammation. Arch Neurol 2007, 64:185-189.
6. Antel J.P., Williams K., Blain M., et al. Oligodendrocyte lysis by CD4+ T cells independent of tumor necrosis factor. Ann Neurol 1994, 35:341-348.
7. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998, 392:565-568.
8. Banati R.B., Newcombe J., Gunn R.N., et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000, 123:2321-2337.
9. Bartholomaus I., Kawakami N., Odoardi F., et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009, 462:94-98.
10. Ben-Nun A., Wekerle H., Cohen I.R. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981, 11:195-199.
11. Bielekova B., Martin R. Development of biomarkers in multiple sclerosis. Brain 2004, 127:1463-1478.
12. Bielekova B., Goodwin B., Richert N., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6:1167-1175.
13. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995, 7:728-735.
14. Black R.A., Rauch C.T., Kozlosky C.J., et al. A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells. Nature 1997, 385:729-733.
15. Brosnan C.F., Raine C.S. Mechanisms of immune injury in multiple sclerosis. Brain Pathol 1996, 6:243-257.
16. Cepok S., Rosche B., Grummel V., et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005, 128:1667-1676.
17. Chan O.T., Hannum L.G., Haberman A.M., et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999, 189:1639-1648.
18. Chandler S., Miller K.M., Clements J.M., et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 1997, 72:155-161.
19. Chao D.T., Korsmeyeer S.J. BCL-2 family: regulators of cell death. Annu Rev Immunol 1998, 16:395-419.
20. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354:610-621.
21. Chinen J., Shearer W.T. Basic and clinical immunology. J Allergy Clin Immunol 2005, 116:411-418.
22. Choi C., Benveniste E.N. Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Brain Res Rev 2004, 44:65-81.
23. Christophi G.P., Panos M., Hudson C.A., et al. Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. Lab Invest 2009, 89:742-759.
24. Codarri L., Fontana A., Becher B. Cytokine networks in multiple sclerosis: lost in translation. Curr Opin Neurol 2010, 23:205-211.
25. Comabella M., Khoury S.J. Immunopathogenesis of multiple sclerosis. Clin Immunol 2011, 142:2-8.
26. Corcione A., Casazza S., Ferretti E., et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A 2004, 101:11064-11069.
27. Cua D.J., Sherlock J., Chen Y., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
28. Cyster J.G. Leukocyte migration: scent of the T zone. Curr Opin Biol 2000, 10:R30-R33.
29. Duddy M.E., Alter A., Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation?. J Immunol 2004, 172:3422-3427.
30. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 2006, 354:942-955.
31. Fugger L. Human autoimmunity genes in mice. Curr Opin Immunol 2000, 12:698-703.
32. Giuliani F., Goodyer C.G., Antel J.P., et al. Vulnerability of human neurons to T cell-mediated cytotoxicity. J Immunol 2003, 171:368-379.
33. Gold R., Hartung H.-P., Lassmann H. T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci 1997, 20:399-404.
34. Gold R., Buttgereit F., Toyka K.V. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 2001, 17:1-8.
35. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
36. Greenfeder S., Umland S.P., Cuss F.M., et al. Th2 cytokines and asthma The role of interleukin-5 in allergic eosinophilic disease. Respir Res 2001, 2:71-79.
37. Greter M., Heppner F.L., Lemos M.P., et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005, 11:328-334.
38. Hemmer B., Archelos J.J., Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002, 3:291-301.
39. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
40. Heppner F.L., Greter M., Marino J., et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 2005, 11:146-152.
41. Hofstetter H.H., Toyka K.V., Tary-Lehmann M., et al. Kinetics and organ distribution of IL-17-producing CD4 cells in proteolipid protein 139-151 peptide-induced experimental autoimmune encephalomyelitis of SJL mice. J Immunol 2007, 178:1372-1378.
42. Hohlfeld R., Kerschensteiner M., Meinl E. Dual role of inflammation in CNS disease. Neurology 2007, 68:S58-S63.
43. Hunter C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005, 5:521-531.
44. Kabat E.A., Wolf A., Bezer A.E. The rapid production of acute disseminated encephalomyelitis in Rhesus monkeys by injection of heterologous and homologous brain tissue with adjuvants. J Exp Med 1947, 85:117-129.
45. Keegan M., Pineda A.A., McClelland R.L., et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002, 58:143-146.
46. Kornek B., Storch M.K., Weissert R., et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000, 157:267-276.
47. Krammer P.H. CD95's deadly mission in the immune system. Nature 2000, 407:789-795.
48. Krishnamoorthy G., Holz A., Wekerle H. Experimental models of spontaneous autoimmune disease in the central nervous system. J Mol Med 2007, 85:1161-1173.
49. Krishnamoorthy G., Saxena A., Mars L.T., et al. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat Med 2009, 15:626-632.
50. Krumbholz M., Theil D., Derfuss T., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005, 201:195-200.
51. Krumbholz M., Theil D., Cepok S., et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006, 129:200-211.
52. Kwidzinski E., Bunse J., Aktas O., et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J 2005, 19:1347-1349.
53. Langrish C.L., Chen Y., Blumenschein W.M., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
54. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol 1990, 8:773-793.
55. Linington C., Bradl M., Lassmann H., et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988, 130:443-454.
56. Lopez-Diego R.S., Weiner H.L. Novel therapeutic strategies for multiple sclerosis - a multifaceted adversary. Nat Rev Drug Discov 2008, 7:909-925.
57. Lucchinetti C., Bruck W., Parisi J., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707-717.
58. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998, 338:436-445.
59. Mackey C.R., Lanzavecchia A., Sallusto F. Chemoattractant receptors and immune responses. Immunologist 1999, 7:112-118.
60. Marta M., Andersson A., Isaksson M., et al. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol 2008, 38:565-575.
61. McMahon E.J., Bailey S.L., Castenada C.V., et al. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005, 11:335-339.
62. Medzhitov R., Janeway C.J. Innate immunity. N Engl J Med 2000, 343:338-344.
63. Meuth S.G., Herrmann A.M., Simon O.J., et al. Cytotoxic CD8+ T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death. J Neurosci 2009, 29:15397-15409.
64. Mix E., Meyer-Rienecker H., Hartung H.P., et al. Animal models of multiple sclerosis - potentials and limitations. Prog Neurobiol 2010, 92:386-404.
65. Moss M.L., Jin S.-L.C., Milla M.E., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumor necrosis factor-α. Nature 1997, 385:733-736.
66. Moynagh P.N. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol 2005, 26:469-476.
67. Muraro P.A., Wandinger K.P., Bielekova B., et al. Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain 2003, 126:20-31.
68. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem 1999, 274:21491-21494.
69. Neumann H., Cavalié A., Jenne D.E., et al. Induction of MHC class I genes in neurons. Science 1998, 269:549-552.
70. Nitsch R., Pohl E.E., Smorodchenko A., et al. Direct impact of T cells on neurons revealed by two-photon microscopy in living brain tissue. J Neurosci 2004, 24:2458-2464.
71. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998, 8:275-283.
72. Odoardi F., Sie C., Streyl K., et al. T cells become licensed in the lung to enter the central nervous system. Nature 2012, 488:675-679.
73. O'Neill L.A. Primer: Toll-like receptor signaling pathways - what do rheumatologists need to know?. Nat Clin Pract Rheumatol 2008, 4:319-327.
74. Owens G.P., Kraus H., Burgoon M.P., et al. Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann Neurol 1998, 43:236-243.
75. Pasare C., Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol 2005, 560:11-18.
76. Paterson P.Y. Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J Exp Med 1960, 111:119-136.
77. Perry A.K., Chen G., Zheng D., et al. The host type I interferon response to viral and bacterial infections. Cell Res 2005, 15:407-422.
78. Peterson J.W., Bo L., Mork S., et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001, 50:389-400.
79. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005, 5:375-386.
80. Prinz M., Garbe F., Schmidt H., et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 2006, 116:456-464.
81. Racke M.K., Drew P.D. Toll-like receptors in multiple sclerosis. Curr Top Microbiol Immunol 2009, 336:155-168.
82. Raine C.S., Cannella B., Hauser S.L., et al. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol 1999, 46:144-160.
83. Ransohoff R.M. EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis. Trends Immunol 2006, 27:167-168.
84. Ransohoff R.M., Tani A., Glabinski A., et al. Chemokines and chemokine receptors in model neurological pathologies: molecular and immunocytochemical approaches. Methods Enzymol 1997, 287:319-348.
85. Reiber H., Ungefehr S., Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 1998, 4:111-117.
86. Reith W., Steimle V., Durand B., et al. Regulation of MHC class II gene expression. Immunobiology 1995, 193:248-253.
87. Schulze-Topphoff U., Prat A., Bader M., et al. Roles of the kallikrein/kinin system in the adaptive immune system. Int Immunopharmacol 2008, 8:155-160.
88. Schulze-Topphoff U., Prat A., Prozorovski T., et al. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 2009, 15:788-793.
89. Segal B.M. CNS chemokines, cytokines, and dendritic cells in autoimmune demyelination. J Neurol Sci 2005, 228:210-214.
90. Serafini B., Rosicarelli B., Magliozzi R., et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004, 14:164-174.
91. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747.
92. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001, 2:762-764.
93. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Proc Natl Acad Sci U S A 2002, 93:2253-2256.
94. Steinman L., Zamvil S.S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol 2005, 26:565-571.
95. 't Hart B.A., Laman J.D., Bauer J., et al. Modelling of multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol 2004, 3:588-597.
96. Touil T., Fitzgerald D., Zhang G.X., et al. Cutting Edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J Immunol 2006, 177:7505-7509.
97. Toyka K.V., Brachman D.B., Pestronk A., et al. Myasthenia gravis: passive transfer from man to mouse. Science 1975, 190:397-399.
98. Trebst C., Ransohoff R.M. Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges. Arch Neurol 2001, 58:1975-1980.
99. von Büdingen H.C., Tanuma N., Villoslada P., et al. Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination. J Clin Immunol 2001, 21:155-170.
100. von Büdingen H.C., Harrer M.D., Kuenzle S., et al. Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies. Eur J Immunol 2008, 38:2014-2023.
101. Wahl S.M., Vazquez N., Chen W. Regulatory T cells and transcription factors: gatekeepers in allergic inflammation. Curr Opin Immunol 2004, 16:768-774.
102. Waxman S.G. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis - current status. Nat Clin Pract Neurol 2008, 4:159-169.
103. Wekerle H., Linington C., Lassmann H. Cellular immune reactivity within the CNS. Trends Neurosci 1986, 9:271-277.
104. Wucherpfennig K.W., Strominger J.L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995, 80:695-705.
105. Wujek J.R., Bjartmar C., Richter E., et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol 2002, 61:23-32.
106. Yong V.W., Krekoski C.A., Forsyth P.A., et al. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998, 21:75-80.
107. Zhang G.X., Baker C.M., Kolson D.L., et al. Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis. Mult Scler 2000, 6:3-13.
108. Zipp F., Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 2006, 29:518-527.
109. Zipp F., Krammer P.H., Weller M. Immune (dys) regulation in multiple sclerosis: role of the CD95-CD95 ligand system. Immunol Today 1999, 20:550-554.
110. Zlotnik A., Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 2000, 12:121-127.